First FDA device panel of 2005
This article was originally published in The Gray Sheet
Executive SummaryPMA to be reviewed at Circulatory System Devices Panel's Jan. 13 meeting in Gaithersburg, Md. likely is Gore's TAG thoracic endoprosthesis. TAG is an ePTFE graft with self-expanding nitinol support for minimally invasive treatment of thoracic aortic aneurysms. Also at the meeting, the agency will update panelists on the FDA Critical Path initiative [Editors' note: To order a webcast of the meeting, visit "The Gray Sheet" affiliate 1FDAadvisorycommittee.com]....
You may also be interested in...
South Korea’s HLB has begun a new growth phase by taking over US-based clinical stage biotech firm Immunomic Therapeutics. Through the acquisition, it is poised to add new pipeline assets including a Phase II vaccine therapy for glioblastoma and proprietary lysosomal targeting technology.
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.
Novartis’s first digital innovation hub in Asia is launched in India, where the Swiss company hopes to ally with partners to deliver digital solutions for patients at scale.